Medine.co.uk

Avipro Salmonella Duo Lyophilisate For Use In Drinking Water

Revised: July 2016

AN: 01137/2015


SUMMARY OF PRODUCT CHARACTERISTICS


1. NAME OF THE VETERINARY MEDICINAL PRODUCT


AviPro SALMONELLA DUO lyophilisate for use in drinking water


2. QUALITATIVE AND QUANTITATIVE COMPOSITION


One dose contains:


Active substances:



*CFU – colony forming units.


Excipients:


For the full list of excipients, see section 6.1.


3. PHARMACEUTICAL FORM


Lyophilisate for use in drinking water.

Appearance: White grey to white brown pellet.


4. CLINICAL PARTICULARS


4.1 Target species


Chickens (future breeders and future layer hens), turkey breeders and turkeys for meat production and ducks for meat production.


4.2 Indications for use, specifying the target species


Chickens (future breeders and future layer hens):

For active immunisation of healthy and susceptible chickens to reduce faecal excretion and colonisation of internal organs with Salmonella Enteritidis and Salmonella Typhimurium field strains and to reduce colonisation of eggs with Salmonella Enteritidis field strains.


Onset of immunity: 15 days.

Duration of immunity: 52 weeks against virulent S. Enteritidis and 46 weeks against virulent S. Typhimurium from the time of the last vaccination when used according to the recommended vaccination schedule.


Turkey breeders and turkeys for meat production:

For active immunisation of healthy and susceptible turkeys to reduce colonisation of internal organs with SalmonellaEnteritidis and SalmonellaTyphimurium field strains.

In general, the colonisation of internal organs of vaccinated turkeys with challenge bacteria is reduced compared to unvaccinated turkeys; a statistically significant reduction could not be shown in all instances.

Onset of immunity: 21 days after first vaccination.

Duration of immunity: for future breeders: 30 weeks against virulent SalmonellaEnteritidis and 28 weeks against virulent SalmonellaTyphimurium from the time of the last vaccination when used according to the recommended vaccination schedule.

for turkeys for meat production: 10 weeks against virulent SalmonellaEnteritidis and against virulent SalmonellaTyphimurium from the time of the last vaccination when used according to the recommended vaccination schedule.


Ducks for meat production:

For active immunisation of healthy and susceptible ducks to reduce colonisation of internal organs with Salmonella Typhimurium field strains.


Onset of immunity: 22 days.

Duration of immunity: 43 days.


4.3 Contraindications


None.


4.4 Special warnings for each target species


In chickens, protection in the presence of maternally derived antibodies has been shown with a vaccine containing SalmonellaEnteriditis but no information is available on the SalmonellaTyphimurium component.


In turkeys, the influence of maternally derived antibodies was not studied.

The prevalence of SalmonellaEnteritidis and SalmonellaTyphimurium in commercial turkey holdings can vary widely amongst the European Union Member States. The vaccine should only be used on turkey farms with known occurrence of SalmonellaEnteritidis or SalmonellaTyphimurium unless national Salmonellacontrol programs in European Union Member States promote control measures such as vaccination.


In ducks, the maternally derived antibodies may have an impact on the development of the immune response.


4.5 Special precautions for use


Special precautions for use in animals


Vaccinate healthy animals only.

Vaccinated chickens may excrete the Salmonella Enteritidis vaccine strain up to 21 days and the Salmonella Typhimurium vaccine strain up to 35 days following vaccination.

Vaccinated ducks may excrete the SalmonellaEnteritidis vaccine strain up to 14 days and the SalmonellaTyphimurium vaccine strain up to 28 days following vaccination.

Shedding of Salmonellavaccine strains in turkeys is intermittent. After vaccinated once at the first day of life, duration of excretion was observed for the SalmonellaEnteritidis vaccine strain up to day 49 and for the SalmonellaTyphimurium vaccine strain up to day 63. After repeated vaccinations duration of excretion is shortened. Due to limited data the eggs of vaccinated turkey breeders are not intended for human consumption.


Not tested on ornamental and pure-bred poultry.

The vaccine can spread to susceptible birds in contact with vaccinated birds.

On very rare occasions, the vaccine strains may be isolated from the environment beyond the above mentioned period when using very sensitive detection methods.


Ensure that the drinking water is free of detergents, disinfectants and acids.

The vaccine strains are highly sensitive to fluoroquinolone antibiotics and have increased sensitivity to erythromycin, chloramphenicol, doxycycline, detergents and environmental noxae.


The differentiation between the vaccine and field strains is achieved by means of an antibiogram:


Salmonella Enteritidis:

In contrast to field strains, the vaccine strain is sensitiveto erythromycin (recommended concentration 15–30 µg/ml) and resistantto streptomycin (recommended concentration 200 µg/ml) and rifampicin (recommended concentration 200 µg/ml).


Salmonella Typhimurium:

In contrast to field strains, the vaccine strain is sensitiveto erythromycin (recommended concentration 15–30 µg/ml) and resistantto nalidixic acid (recommended concentration 20 µg/ml) and rifampicin (recommended concentration 200 µg/ml).


Depending on the test system used, oral vaccination may result in low seropositive reactions of individual birds in a flock. Since the serological monitoring of Salmonellais only a flock test, positive findings have to be confirmed, e.g. by bacteriology.


Special precautions to be taken by the person administering the veterinary medicinal product to animals


Personal protective equipment consisting of gloves should be worn when handling the veterinary medicinal product.

Open the vial only under water to avoid aerosols.

Wash and disinfect hands after handling the vaccine.

Do not ingest. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

The vaccine strains are sensitive to a number of antibiotics including quinolones (ciprofloxacin).


Since the vaccine has been prepared with live, attenuated microorganisms, appropriate measures should be taken to prevent contamination of the handler and other people that collaborate in the process.


Vaccinated animals may excrete the vaccine strains. Immunocompromised persons are advised to avoid contact with the vaccine and recently vaccinated animals.


The veterinary medicinal product should not be administered by pregnant women.

Personnel involved in attending vaccinated animals should follow general hygiene principals (changing clothes, wearing gloves, cleaning and disinfection of boots) and take particular care in handling litter from vaccinated chickens until 35 days after vaccination, from vaccinated ducks until 28 days after vaccination and from vaccinated turkeys until 63 days after vaccination.


4.6 Adverse reactions (frequency and seriousness)


None known.


4.7 Use during pregnancy, lactation or lay


Do not use in chickens in lay and within 3 weeks before the onset of the laying period.

Do not use in ducks intended for lay.

Do not use in turkeys in lay and within 5 weeks before the onset of the laying period.


4.8 Interaction with other medicinal products and other forms of interaction


Since the vaccine strains are live bacteria, simultaneous use of chemotherapeutics which are effective against Salmonellashould be avoided. However, if this is inevitable, the flock must be re-immunised. A decision to use this vaccine before or after any chemotherapeutic treatment needs to be taken on a case-by-case basis.


No information is available on the safety and efficacy of this vaccine when used with other veterinary medical product. A decision to use this vaccine before or after any other veterinary medicinal product therefor needs to be made on a case-by-case basis.


4.9 Amounts to be administered and administration route


For oral use after resuspension in drinking water.


Advice on correct administration:


The contents of opened bottles should be used completely.

Prepare only the amounts of the vaccine that will be used within 4 hours.

Protect the reconstituted vaccine from direct sunlight, frost and temperatures above 25 °C.

Follow these instructions for correct administration, so that all birds receive the appropriate dose.


Vaccination scheme:


AviPro SALMONELLA DUO may be used from the 1stday of life.


Ducks for meat production:A single dose from first day of life.


Chickens (future breeders and future layer hens):A single dose from first day of life followed by a second vaccination at an age of 6 to 8 weeks and a third vaccination around the 16thweek of life at least 3 weeks before onset of lay.


Turkeys for meat production:A single dose from the first day of life followed by a second vaccination at an age of 6 weeks.


Turkey breeders:A single dose from the first day of life followed by a second vaccination at an age of 6 weeks, a third vaccination at an age of 16 weeks and a fourth vaccination at an age of 23-24 weeks.


Administration via the drinking water:


Determination of the required amount of water:



Resuspension of the lyophilisate:



Application of the resuspended vaccine:



4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary


No adverse reactions are known after an overdose.


4.11 Withdrawal period(s)


For chicken and ducks: meat, offal and eggs: 21 days.

For turkeys: meat and offal: 70 days after the first vaccination,

49 days after repeated vaccination.


5. IMMUNOLOGICAL PROPERTIES


Pharmacotherapeutic group: immunologicals for Aves, live bacterial vaccines for domestic fowl, turkeys and ducks.

ATCvet code: QI01AE01, QI01BE01, QI01CE01.


AviPro SALMONELLA DUO stimulates active immunity against Salmonella Enteritidis and against Salmonella Typhimurium.


The vaccine strains are natural metabolic drift mutants, i.e. they lack or do not express certain metabolic pathways which result in attenuation.


The genetic basis results in defective ribosomal protein S12 affecting polypeptide synthesis (streptomycin resistance), defective gyrase affecting DNA replication (nalidixic acid resistance) and defective RNA polymerase affecting transcription of DNA to RNA (rifampicin resistance).


The vaccine strains also have attenuations that increase the permeability of the cell membrane for harmful agents such as detergents and antibiotics. This means that the strains have poor survival in the environment and are highly sensitive to fluoroquinolones and unlike field strains are sensitive to erythromycin.


6. PHARMACEUTICAL PARTICULARS


6.1 List of excipients


Soy peptone

Sucrose

Gelatine

HEPES buffer


6.2 Incompatibilities


Do not mix with any other veterinary medicinal product.


6.3 Shelf life


Shelf life of the veterinary medicinal product as packaged for sale: 18 months.

Shelf life after reconstitution according to directions: 4 hours.


6.4 Special precautions for storage


Store and transport refrigerated (2 C – 8 C).

Do not freeze.

Protect from direct sunlight.

6.5 Nature and composition of immediate packaging


Type I (Ph. Eur.) 20 ml glass vials with welt edge and rubber stopper. The vials are sealed with aluminium tear-off caps.


The vaccine is available in the following pack sizes:


Cardboard box with 1 vial containing 1,000 vaccine doses.

Cardboard box with 1 vial containing 2,000 vaccine doses.


Bundle packs:

Cardboard box with 10 vials containing of 1,000 vaccine doses.

Cardboard box with 10 vials containing of 2,000 vaccine doses.


Not all pack sizes may be marketed.


6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products


Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.


7. MARKETING AUTHORISATION HOLDER


Lohmann Animal Health GmbH

Heinz – Lohmann Str. 4

27472 Cuxhaven

Germany


8. MARKETING AUTHORISATION NUMBER


Vm 16894/4009


9. DATE OF FIRST AUTHORISATION


22 July 2011


10. DATE OF REVISION OF THE TEXT


July 2016


PROHIBITION OF SALE, SUPPLY AND/OR USE


Not applicable.




Approved: 28 July 2016


Page 7 of 7